Current pathological IHC methods are based on the assessment of a proportion of HER2-positive tumor cells; however, ITH of HER2 expression may present a challenge in some tumors to be categorized with a single value (0, 1+, 2+, and 3+). This evidence concerns the gene ERBB2 and neoplasm.